Ab therapy of AML: Native anti-CD33 Ab and drug conjugates Journal Article
| Author: | Jurcic, J. G. |
| Article Title: | Ab therapy of AML: Native anti-CD33 Ab and drug conjugates |
| Abstract: | MAb have become an important treatment modality in cancer therapy. Genetically engineered chimeric and humanized Ab have demonstrated activity against a variety of tumors. While the humanized anti-CD33 MAb lintuzumab has only modest single-agent activity against overt AML, it can eliminate minimal residual disease detectable by reverse transcription-PCR in acute promyelocytic leukemia. Targeted chemotherapy with the anti-CD33-calicheamicin construct gemtuzumab ozogamicin has produced remissions in patients with relapsed AML and appears promising when used in combination with standard chemotherapy in the treatment of newly diagnosed AML. |
| Keywords: | cancer survival; unclassified drug; acute granulocytic leukemia; overall survival; fludarabine; clinical trial; review; cytotoxic agent; drug safety; monotherapy; nonhuman; side effect; unspecified side effect; disease free survival; cytarabine; topotecan; interleukin 2; low drug dose; reverse transcription polymerase chain reaction; liver toxicity; multiple cycle treatment; etoposide; combination chemotherapy; cyclophosphamide; antineoplastic activity; monoclonal antibodies; aminotransferase blood level; drug dose escalation; arsenic trioxide; hematologic malignancy; myelodysplastic syndrome; nonhodgkin lymphoma; drug mechanism; minimal residual disease; drug response; mitoxantrone; daunorubicin; promyelocytic leukemia; allogeneic hematopoietic stem cell transplantation; hyperbilirubinemia; leukocyte count; liver function test; maximum tolerated dose; idarubicin; anthracycline derivative; leukemia relapse; chronic lymphatic leukemia; leukocytosis; retinoic acid; drug binding; gemtuzumab ozogamicin; antibody dependent cellular cytotoxicity; adult respiratory distress syndrome; leukemia remission; retinoic acid receptor alpha; hum195; myeloid leukemia; lung edema; acute myeloid leukemia; lintuzumab; monoclonal antibody m 195; sgn 33; liver vein obstruction; plasma half life |
| Journal Title: | Cytotherapy |
| Volume: | 10 |
| Issue: | 1 |
| ISSN: | 1465-3249 |
| Publisher: | Elsevier Science Ltd. |
| Date Published: | 2008-01-01 |
| Start Page: | 7 |
| End Page: | 12 |
| Language: | English |
| DOI: | 10.1080/14653240701519012 |
| PROVIDER: | scopus |
| PUBMED: | 17917880 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 17 November 2011" - "CODEN: CYTRF" - "Source: Scopus" |
